SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -585% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -9,187.7% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -9,934.5% |
| EPS Diluted | -0.21 | -1.09 | -0.56 | -1.23 |
| % Growth | 80.7% | -94.6% | 54.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |